Faheem Hasnain

CIK: 0001352620

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)2 (5.9%)

Position reduction

Option Exercises (M)2 (5.9%)

Derivative conversions

Awards (A)17 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)13 (38.2%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

ASPE

Aspen Neuroscience, Inc.

DirectorOfficer

GOSS

Gossamer Bio, Inc.

DirectorOfficer

KURA

Kura Oncology, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (34 total)

ASPE
Aspen Neuroscience, Inc.
Nov 2, 2026
Conversion(C)
Indirect
7.1K shares-
ASPE
Aspen Neuroscience, Inc.
Nov 2, 2026
Conversion(C)
Indirect
14.9K shares-
ASPE
Aspen Neuroscience, Inc.
Nov 2, 2026
Conversion(C)
Indirect
14.3K shares-
GOSS
Gossamer Bio, Inc.
Aug 24, 2026
Award(A)
Pre-Funded Warrant (Right to Buy)
Indirect
166 shares at avg. $1000.00-
GOSS
Gossamer Bio, Inc.
Aug 24, 2026
Award(A)
Stock Option (Right to Buy)
Direct
5.8M shares-
KURA
Kura Oncology, Inc.
Jun 4, 2026
Award(A)
Option to purchase common stock
Direct
35K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
1.7M shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
1.5M shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
1.3M shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
437.5K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
544.5K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
544.5K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
650K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
325K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
47K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
43.5K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Award(A)
Stock Option (Right to Buy)
Direct
1.7M shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Award(A)
Stock Option (Right to Buy)
Direct
1.5M shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Award(A)
Stock Option (Right to Buy)
Direct
1.3M shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Award(A)
Stock Option (Right to Buy)
Direct
544.5K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Award(A)
Stock Option (Right to Buy)
Direct
437.5K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Award(A)
Stock Option (Right to Buy)
Direct
43.5K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Award(A)
Stock Option (Right to Buy)
Direct
47K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Award(A)
Stock Option (Right to Buy)
Direct
325K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Award(A)
Stock Option (Right to Buy)
Direct
650K shares-

		Type	Shares	Price		Ownership
Nov 2, 2026	ASPE Aspen Neuroscience, Inc.	Conversion(C)	7,120	-	$0	Indirect
Nov 2, 2026	ASPE Aspen Neuroscience, Inc.	Conversion(C)	14,913	-	$0	Indirect
Nov 2, 2026	ASPE Aspen Neuroscience, Inc.	Conversion(C)	14,316	-	$0	Indirect
Aug 24, 2026	GOSS Gossamer Bio, Inc.	Award(A) Pre-Funded Warrant (Right to Buy)	166	$1000.00	-	Indirect
Aug 24, 2026	GOSS Gossamer Bio, Inc.	Award(A) Stock Option (Right to Buy)	5,800,051	-	-	Direct
Jun 4, 2026	KURA Kura Oncology, Inc.	Award(A) Option to purchase common stock	35,000	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Disposition(D) Stock Option (Right to Buy)	1,680,000	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Disposition(D) Stock Option (Right to Buy)	1,540,000	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Disposition(D) Stock Option (Right to Buy)	1,312,500	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Disposition(D) Stock Option (Right to Buy)	437,500	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Disposition(D) Stock Option (Right to Buy)	544,500	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Disposition(D) Stock Option (Right to Buy)	544,500	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Disposition(D) Stock Option (Right to Buy)	650,000	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Disposition(D) Stock Option (Right to Buy)	325,000	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Disposition(D) Stock Option (Right to Buy)	47,000	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Disposition(D) Stock Option (Right to Buy)	43,500	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Award(A) Stock Option (Right to Buy)	1,680,000	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Award(A) Stock Option (Right to Buy)	1,540,000	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Award(A) Stock Option (Right to Buy)	1,312,500	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Award(A) Stock Option (Right to Buy)	544,500	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Award(A) Stock Option (Right to Buy)	437,500	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Award(A) Stock Option (Right to Buy)	43,500	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Award(A) Stock Option (Right to Buy)	47,000	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Award(A) Stock Option (Right to Buy)	325,000	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Award(A) Stock Option (Right to Buy)	650,000	-	-	Direct

1-25 of 34 transactions

About Hasnain Faheem

Hasnain Faheem (SEC CIK 0001352620) files insider reports with the SEC as Executive Chair of Aspen Neuroscience, Inc. (ASPE), President & CEO of Gossamer Bio, Inc. (GOSS) and Director of Kura Oncology, Inc. (KURA).

Signal8 holds 11 ownership filings by Hasnain Faheem (1 Form 3, 10 Form 4), filed between Mar 6, 2025 and Nov 2, 2026. Those filings report 34 transactions, from Mar 4, 2025 to Nov 2, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Hasnain Faheem's filings is in SAN DIEGO, CA.

Recent filings by Hasnain Faheem

Nov 2, 2026: Conversions of ASPE shares (3 lines, Form 4, code C).
Aug 24, 2026: Grants or awards of GOSS derivative securities (2 lines, Form 4, code A).
Jun 4, 2026: Grant or award of KURA derivative securities (Form 4, code A).
Mar 19, 2026: Disposition to issuer transactions of GOSS derivative securities (10 lines, Form 4, code D).
Mar 19, 2026: Grants or awards of GOSS derivative securities (9 lines, Form 4, code A).

Other insiders filing for Aspen Neuroscience, Inc. (ASPE)

ARCH Venture Fund X, L.P., 10% Owner
ARCH Venture Partners XIV, L.P., 10% Owner
Spaventa Andrew, Director
ORBIMED ADVISORS LLC, Director
Boerneke Jeffrey Lee, General Counsel and Secretary
Daniel Thomas O, Director

How to read Form 4 transaction codes